An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs MDNA 55 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 10 Oct 2017 According to a Medicenna Therapeutics media release, data were presented at the 2017 Congress of Neurological Surgeons.
- 28 Sep 2017 According to a Medicenna Therapeutics media release, safety and pharmacokinetic date will be presented at the Congress of Neurological Surgeons conference 2017 in Boston.
- 28 Sep 2017 Based on a planned safety analysis following a unanimous recommendation from MDNA55's Safety Review Committee (SRC), after enrollment of the first six patients, Medicenna has implemented the updated protocol following its submission to the USFDA and approval by the Institutional Review Boards (IRBs). The amended protocol includes an enhanced drug delivery procedure, dose doubled to 3.0mg/mL and administered as a maximized volume of 60mL, planned patient number changed from 43 to 52.